leisure time -WSS

leisure time

author：entertainment 2025-09-29 19:07:02 - browse：9665

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Judge in Trump's classified documents case questions use of out

focus

WSS

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Feed a cold, starve a fever? Here’s what science says

Election results set back Medicaid expansion plans

Flash flood warnings continue for parts of Missouri, Illinois

Sweden knocks USA out of World Cup in penalty kicks

Trump used to be more articulate. What could explain the change?

hotspot

leisure time

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: Live from the 2023 STAT Summit

Guidelines to prevent youth baseball injuries need more muscle

Sweden knocks USA out of World Cup in penalty kicks

Novavax promises a turnaround & Lilly roils the obesity market

Failure, not just success, should guide future doctors

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Medicare details structure of new drug price negotiation program

How CRISPR works, explained in two minutes

explore

Restaurant meals are packed with calories, and we still keep eating them

Doctors are clamoring for more clarity on Paxlovid prescribing

How AI can help patients find reliable information about doctors

How AI can help patients find reliable information about doctors

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Google's generative AI to analyze medical images — and talk to docs

focus

focus

hotspot

entertainment